Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Zymeworks (ZYME) EBITDA (2021 - 2025)

Zymeworks' EBITDA history spans 5 years, with the latest figure at -$41.2 million for Q4 2025.

  • On a quarterly basis, EBITDA fell 68.6% to -$41.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$80.3 million, a 34.77% increase, with the full-year FY2025 number at -$80.3 million, up 34.77% from a year prior.
  • EBITDA hit -$41.2 million in Q4 2025 for Zymeworks, down from -$19.3 million in the prior quarter.
  • Over the last five years, EBITDA for ZYME hit a ceiling of $309.4 million in Q4 2022 and a floor of -$72.6 million in Q1 2022.
  • Historically, EBITDA has averaged -$16.5 million across 5 years, with a median of -$31.0 million in 2023.
  • Biggest five-year swings in EBITDA: skyrocketed 890.33% in 2022 and later plummeted 104.13% in 2023.
  • Tracing ZYME's EBITDA over 5 years: stood at -$39.2 million in 2021, then skyrocketed by 890.33% to $309.4 million in 2022, then plummeted by 104.13% to -$12.8 million in 2023, then plummeted by 91.28% to -$24.5 million in 2024, then plummeted by 68.6% to -$41.2 million in 2025.
  • Business Quant data shows EBITDA for ZYME at -$41.2 million in Q4 2025, -$19.3 million in Q3 2025, and $2.4 million in Q2 2025.